SEATTLE CHILDREN’S signed a letter of intent with Juno Therapeutics Inc. to expand their collaboration to accelerate the availability of T-cell immunotherapy clinical trials for children and adults with brain tumors. The aim of the collaboration is to fast-track clinical implementation with the goal of opening phase I clinical trials within the next two years....
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
